表紙
市場調查報告書
商品編碼
999511

中國的Hydroxychloroquine市場的相關調查報告書(2021年-2025年)

Investigation Report on China's Hydroxychloroquine Market, 2021-2025

出版日期: | 出版商: China Research and Intelligence | 英文 50 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在中國市場的Hydroxychloroquine銷售,從2016年到2020年期間以7.34%的年複合成長率成長,從2016年的2億5,800萬元踏實增加到2020年的3億4,300萬元。2020年銷售,自2019年略為增加0.71%。

用於2020年初的實驗性預防、治療時,短期性銷售量增加,今後慢慢返回到原來的銷售量。Hydroxychloroquine,主要用於瘧疾和類風濕性關節炎的治療。

本報告提供中國的Hydroxychloroquine市場的相關調查,市場規模,主要製造商及價格,給予市場發展的影響的主要原因,市場預測,COVID-19的影響等資訊。

目錄

第1章 Hydroxychloroquine的相關概念

  • Hydroxychloroquine的適應症
  • 中國的Hydroxychloroquine的開發
  • 中國的Hydroxychloroquine的政府核准
  • COVID-19對中國的Hydroxychloroquine市場的影響

第2章 中國的Hydroxychloroquine銷售(2016-2020)

  • Hydroxychloroquine的銷售額
    • 整體銷售額
    • 各地區銷售額
  • Hydroxychloroquine的銷售量
    • 整體銷售量
    • 各地區銷售量
  • 各劑型:中國的Hydroxychloroquine銷售(2016-2020)

第3章 中國的主要Hydroxychloroquinemeka分析(2016-2020)

  • 主要Hydroxychloroquinemeka的市場佔有率相關分析
    • 各銷售額的市場佔有率
    • 各銷售量的市場佔有率
  • Shanghai Zhongxi Pharmaceutical Co.,Ltd.
    • 企業簡介
    • 中國的Shanghai Zhongxi Pharmaceutical Co.,Ltd.的Hydroxychloroquine(Fenle)銷售
  • Sanofi-aventis Ireland Ltd
    • 企業簡介
    • 中國的Sanofi-aventis Ireland Ltd的Hydroxychloroquine(Plaquenil)銷售

第4章 中國的Hydroxychloroquine的價格(2020-2021)

  • Shanghai Zhongxi Pharmaceutical(Fenle)
  • Sanofi-aventis Ireland (Plaquenil)

第5章 中國的Hydroxychloroquine市場預測(2021-2025)

  • 市場發展的影響因素分析
  • 中國的非專利Hydroxychloroquine的進步
  • 市場趨勢預測
目錄
Product Code: 2104458

Hydroxychloroquine is commonly used to prevent and treat malaria. The pharmacokinetics of hydroxychloroquine is similar to that of chloroquine. It can be rapidly absorbed in the gastrointestinal tract and excreted in the kidneys. Hydroxychloroquine is also used in the treatment of rheumatoid arthritis, lupus erythematosus, and delayed skin lesions purpura.

The sales of hydroxychloroquine in the Chinese market have been rising steadily, from CNY 258 million in 2016 to CNY 343 million in 2020, with a CAGR of 7.34% from 2016 to 2020. In 2020, China's sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.

The market demand for hydroxychloroquine in China is relatively large. There are two companies approved for manufacturing hydroxychloroquine, namely Shanghai Zhongxi Pharmaceutical Co., Ltd. and Sanofi-aventis Ireland Ltd. Shanghai Zhongxi Pharmaceutical Co., Ltd. has a larger sales market share with lower prices advantage. In 2020, the sales amount of Shanghai Zhongxi Pharmaceutical is as high as CNY 233 million, and the market share is 68.05%.

Hydroxychloroquine has been tried out in search for its effectiveness of prevention and treatment for coronavirus diseases in the first half of 2020. In March 2020, the Shanghai Municipal Health Commission in China recommended that hydroxychloroquine be used to treat mild to moderate new coronavirus diseases. The preliminary results of clinical studies in China and France showed that hydroxychloroquine is effective and safe. On March 28, 2020, the U.S. Food and Drug Administration issued Emergency Use Authorization (EUA) for use of Hydroxychloroquine Sulfate for treatment of 2019 Coronavirus disease. However, on July 4, 2020, the World Health Organization announced that it would stop the hydroxychloroquine trial on the grounds because "the mortality rate of hospitalized patients with coronary disease could not be relieved during the trial". In August 2020, the "COVID-19 Diagnosis and Treatment Plan (Trial Eighth Edition)" issued by the National Health Commission of China stated that "hydroxychloroquine or combined use with azithromycin is not recommended."

The sales volume increased in the short term when used in the experimental prevention and treatment at the beginning of 2020. It is predicted that its sales will gradually return to the original level, that is, it is mainly used for the treatment of malaria and rheumatoid arthritis.

Topics covered:

  • The impact of COVID-19 on China's hydroxychloroquine market
  • Market size of hydroxychloroquine in China
  • Major R hydroxychloroquine manufacturers in China
  • Prices of hydroxychloroquine in China
  • Major factors affecting the development of China's hydroxychloroquine market
  • Prospect of China's hydroxychloroquine market

Table of Contents

1 Relevant Concepts of Hydroxychloroquine

  • 1.1 Indications for Hydroxychloroquine
  • 1.2 Development of Hydroxychloroquine in China
  • 1.3 Governmental Approval of Hydroxychloroquine in China
  • 1.4 The impact of COVID-19 on China's Hydroxychloroquine market

2 Sales of Hydroxychloroquine in China, 2016-2020

  • 2.1 Sales Value of Hydroxychloroquine
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Hydroxychloroquine
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Hydroxychloroquine by Dosage Form in China, 2016-2020

3 Analysis of Major Hydroxychloroquine Manufacturers in China, 2016-2020

  • 3.1 Analysis on Market Share of Major Hydroxychloroquine Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Shanghai Zhongxi Pharmaceutical Co.,Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Shanghai Zhongxi Pharmaceutical's Hydroxychloroquine (Fenle) in China
  • 3.3 Sanofi-aventis Ireland Ltd
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Sanofi-aventis Ireland's Hydroxychloroquine (Plaquenil) in China

4 Prices of Hydroxychloroquine in China, 2020-2021

  • 4.1 Shanghai Zhongxi Pharmaceutical (Fenle)
  • 4.2 Sanofi-aventis Ireland (Plaquenil)

5 Prospect of China's Hydroxychloroquine Market, 2021-2025

  • 5.1 Analysis on Factors Affecting Development of China's Hydroxychloroquine Market
  • 5.2 Progress of Generic Hydroxychloroquine in China
  • 5.3 Forecast on Trend of Hydroxychloroquine Market

Selected Charts

  • Chart Approval information for Hydroxychloroquine in China
  • Chart Hydroxychloroquine sales in the Chinese market, 2016-2020
  • Chart Hydroxychloroquine sales value in some regions of China, 2016-2020
  • Chart China's Hydroxychloroquine sales volume, 2016-2020
  • Chart Hydroxychloroquine Sales Volume in Some Regions of China, 2016-2020
  • Chart Shanghai Zhongxi Pharmaceutical's Hydroxychloroquine sales value in China, 2016-2020
  • Chart Shanghai Zhongxi Pharmaceutical's Hydroxychloroquine sales volumes in China, 2016-2020
  • Chart Sanofi-aventis Ireland's sales value of Hydroxychloroquine, 2016-2020
  • Chart Sanofi-aventis Ireland's sales volume of Hydroxychloroquine, 2016-2020
  • Chart Shanghai Zhongxi Pharmaceutical's Hydroxychloroquine (Fenle) price in some parts of China, 2020-2021
  • Chart Sanofi-aventis Ireland's Hydroxychloroquine (Plaquenil) price in some parts of China, 2020-2021
  • Chart Hydroxychloroquine sales value forecast in China's market, 2021-2025